Papers

Eprinomectin: a derivative of Ivermectin SUPPRESSES GROWTH AND METASTATIC PHENOTYPES OF PROSTATE CANCER cells by targeting the β-catenin signaling pathway

• https://link.springer.com/article/10.1007/s00432-023-04829-5

___• https://archive.md/Ycxty

___• https://web.archive.org/web/20231008143657/https://link.springer.com/article/10.1007/s00432-023-04829-5

• Author: Angela Samy, Mohamed Ali Hussein, Gnanasekar Munirathinam

Ivermectin SUPPRESSES PANCREATIC CANCER via mitochondria dysfunction

• https://aacrjournals.org/cancerres/article/82/12_Supplement/2320/701043

___• https://archive.md/4EaJG

___• https://web.archive.org/web/20231008143718/https://aacrjournals.org/cancerres/article/82/12_Supplement/2320/701043

• Author: Daeun Lee, Joon Seong Park, Yun Sun Lee

Ivermectin has New Application in INHIBITING COLORECTAL CANCER Cell Growth

• https://www.frontiersin.org/articles/10.3389/fphar.2021.717529/full

___• https://archive.li/Fn3aE

___• https://web.archive.org/web/20230720061933/https://www.frontiersin.org/articles/10.3389/fphar.2021.717529/full

• Author: Shican Zhou, Hang Wu, Wenjuan Ning

Anti-parasitic Drug Ivermectin Exhibits POTENT ANTICANCER ACTIVITY Against Gemcitabine-resistant Cholangiocarcinoma In Vitro

• https://ar.iiarjournals.org/content/39/9/4837.full

___• https://archive.md/pPxW9

___• https://web.archive.org/web/20231003152611/https://ar.iiarjournals.org/content/39/9/4837.full

• Author: Kitti Intuyod, Chariya Hahnvajanawong, Porntip Pinlaor

NIH: Ivermectin, a POTENTIAL ANTICANCER DRUG derived from an antiparasitic drug

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/

___• https://archive.md/S9QuS

___• https://web.archive.org/web/20230831120431/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505114/

• Author: Mingyang Tang, Xiaodong Hu, Yi Wang

• Video à https://www.bitchute.com/video/NadONSYKjQKU/

___• https://web.archive.org/web/20230708221126/https://www.bitchute.com/video/NadONSYKjQKU/

Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in LUNG ADENOCARCINOMA CELLS

• https://link.springer.com/article/10.1007/s00280-023-04589-6

___• https://archive.md/Zavbu

___• https://web.archive.org/web/20231008143739/https://link.springer.com/article/10.1007/s00280-023-04589-6

• Author: Man-Yuan Li, Jiao Zhang, Xiao Lu

The ANTICANCER POTENTIAL OF IVERMECTIN: Mechanisms of Action and Therapeutic Implications

• https://jlar.rovedar.com/index.php/JLAR/article/view/11

___• https://archive.md/n4304

___• https://web.archive.org/web/20230803124614/https://jlar.rovedar.com/index.php/JLAR/article/view/11

• Author: Narges Lotfalizadeh, Arian Gharib, Ashkan Hajjafari

Progress in Understanding the Molecular Mechanisms Underlying the ANTITUMOUR EFFECTS OF IVERMECTIN

• https://www.tandfonline.com/doi/full/10.2147/DDDT.S237393

___• https://archive.md/kUoep

___• https://web.archive.org/web/20230000000000*/https://www.tandfonline.com/doi/full/10.2147/DDDT.S237393

• Author: Jian Liu, Kun Zhang, Lin Cheng

The multitargeted drug ivermectin: from an antiparasitic agent to A REPOSITIONED CANCER DRUG

• https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/

___• https://archive.md/tW2zF

___• https://web.archive.org/web/20231008143705/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835698/

• Author: Mandy Juarez, Alejandro Schcolnik-Cabrera, Alfonso Dueñas-Gonzalez

Source

Dr. William Makis. In his "COVID Intel" publication at https://makismd.substack.com/p/ivermectin-and-cancer-it-has-at-least/comments

This publication above is visible only to his paid subscribers

I do not have a conflict of interest with any of the above

Disclaimer

This blog is about expressing my opinions, feelings, and thoughts. Nothing else. In other words, but not limited to, my blog is NOT a recommendation, NOT an advice, NOT a call for violence to self or others, NOT an endorsement. If you need recommendation of any kind, such as but not limited to, medical or legal recommendation, I suggest considering asking an appropriate professional to your liking. I suggest choosing one without conflict of interest.